Drugs / pCAR-19B cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04888468 | Nov 2019 → Jun 2021 | B-cell childhood acute lymphoblastic leukemia | Chongqing Precision Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05334823 | Jan 2022 → Dec 2024 overdue | childhood acute lymphoblastic leukemia | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pCAR-19B cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05334823 ↗ |
| Modality | Cell therapy | “Anti-CD19 CAR-T Therapy (pCAR-19B)” NCT04888468 ↗ |
| Route | Intravenous | “pCAR-19B will be infused to the subject by intravenous infusion.” NCT04888468 ↗ |
| Target | CD19 | “Anti-CD19 CAR-T Therapy (pCAR-19B)” NCT04888468 ↗ |